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measurement (16 items, 5-point Likert-scale) as well as DCE (8
pairs with 8 characteristics). The DCE pairs were generated at
random. Analyses of variance, inﬂuencing factors, random effect
probit and logit models for the DCE were performed. RESULTS:
282 patients responded of which 54% were male: mean age 62
years (SD = 10 years), mean duration of the disease ﬁve years
(SD = 3.8 years). Direct measurement revealed efﬁcacy aspects
and further treatment options as most important followed by
prolonged life expectancy, less side effects, therapy-free-intervals
and ﬂexibility. All aspects showed mean values above 50 points
(scale 0–100). In the DCE, alternatives which especially con-
tained one or more of the aspects further treatment options,
longer life expectancy, “Not-always-think-of-the-disease” and
therapy-free-intervals were more frequently selected than others.
CONCLUSIONS: Further treatment options are of major impor-
tance to MM patients. In addition, patients value treatment-free-
lifetime and emotional quality especially if they are not
continuously reminded of the disease. Combining direct mea-
surement of patients preferences with choice based measure-
ments like the DCE ensures eliciting important treatment aspects
and avoids ceiling effects and “all-is-very-important” results.
REMARKS: Patient-advocacy-groups Arbeitsgemeinschaft
Plasmozytom/Mulitples Myelom and Deutsche Leukämie- &
Lymphom-Hilfe helped organizing the surveys.
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OBJECTIVES: Prostate cancer is the second leading cause of
cancer mortality in American men. Androgen deprivation
therapy (ADT) is the standard initial treatment for advanced
disease, but most patients eventually develop HRPC. There are
no universally accepted, standardized and objective criteria for
assessing response to treatment for HRPC, so patient-reported
outcomes (PRO) are a critical in guiding and monitoring pallia-
tive interventions. We characterized the prevalence and natural
history of symptoms in patients with hormone refractory, incur-
able prostate cancer. METHODS: Patients with HRPC receiving
care at Dana-Farber Cancer Institute, completed a questionnaire
at each clinic visit over 10 months, comprising the Quality of Life
Index (QLI), Rotterdam Symptom Checklist (RSCL), Brief Pain
Inventory (BPI), Hospital Anxiety and Depression Scale (HADS),
American Urological Association symptom index (AUA), and the
ECOG performance status scale. RESULTS: A total of 87 of 102
eligible patients enrolled. Among participants, the survey
response rate was 98%. A total of 87% had documented
metastases; the remainder had rising prostate speciﬁc antigen
levels despite ADT. The following frequencies of symptoms were
reported at baseline and during follow-up (worst scores ever),
respectively: urinary symptoms, moderate/severe: 62 v. 75%; any
pain, 67 v. 70%; severe intensity in worst pain score, 19 v. 25%;
HADS possible/probable diagnosis: anxiety, 21 v. 39%, depres-
sion, 20 v. 35%; ECOG PS 2+, 15 v. 37%; RSCL symptoms:
tiredeness, 30 v. 60%; lack of energy, 28 v. 58%; muscle soreness,
26 v. 45%. The mean overall health rating (0 = worst,
100 = best) was, 74 at baseline v. 56 during follow up. A shift
toward lower levels of HRQL was also observed across all
domains of the QLI. CONCLUSIONS: Patients with HRPC
endure a substantial and worsening symptom burden over time.
Given the high prevalence of symptoms and difﬁculty of assessing
treatment response by objective measures in this disease, PRO
should be routinely incorporated into clinical care and trials.
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OBJECTIVES: Panitumumab, a fully human anti-EGFr mono-
clonal antibody, is approved in Europe as monotherapy for
mCRC patients with wild-type (non-mutated) KRAS tumors. In
a randomized phase 3 trial, chemorefractory mCRC patients
receiving panitumumab plus BSC had signiﬁcantly longer
progression-free survival vs. BSC alone. Analyses of the KRAS
gene showed that all responders had wild type KRAS. This
analysis evaluates patient-reported outcomes (PROs) by KRAS
status. METHODS: In the phase 3 trial, mCRC patients with
disease progression after standard chemotherapy were random-
ized 1:1 to panitumumab (6 mg/kg Q2W) plus BSC vs. BSC
alone. KRAS status was assessed in 427/463 (92%) patients.
Analyses of PROs included HRQOL (EQ-5D) and CRC symp-
toms (NCCN/FACT CRC Symptom Index, FCSI). Linear mixed
models estimating change from baseline in PRO scores were
employed. Sensitivity analysis using pattern-mixture models
evaluated the appropriateness of the assumption that PRO data
were missing at random. Pattern-mixture models can provide
unbiased estimates of treatment effects, taking into account
missing data patterns. ANCOVA of the time-adjusted AUC using
last value carried forward (LVCF) and slope imputation methods
were also used. RESULTS: There were 363/427 (85%) patients in
the KRAS-PRO analysis set (188 panitumumab [112 wild-type
KRAS; 76 mutant KRAS]; 175 BSC [96 wild-type KRAS; 79
mutant KRAS]). Linear mixed models showed signiﬁcant differ-
ences in CRC symptoms and HRQOL in favor of panitumumab
in patients with wild-type KRAS. No differences were observed
in patients with mutant KRAS. Pattern-mixture analysis showed
that signiﬁcant differences in CRC symptoms (FCSI scores: dif-
ference in LS adjusted means [95%CI]; 5.746 [1.448, 10.044]
and HRQOL (EQ-5D scores: difference in LS adjusted means
[95%CI]; 0.319 [0.184, 0.454]) in favor of panitumumab treated
patients with wild-type KRAS were particular to patients who
progressed greater or equal to 9 weeks. CONCLUSIONS: Pani-
tumumab patients with wild-type KRAS showed signiﬁcantly
better HRQOL and CRC symptoms compared to BSC alone.
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OBJECTIVES: Even though chemotherapies of advanced
non-small cell lung cancer (NSCLC) are improving patients’ out-
comes, usually patients’ treatment preferences are underesti-
mated by physicians. To identify those attributes related to
chemotherapy treatment that is highly valued by patients
with advanced NSCLC. METHODS: An observational, cross-
sectional study was carried out. A four attributes treatment
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